Adamed reckons Jelfa is just what the doctor ordered - but will ARP concur?

"We are interested in its manufacturing potential. Moreover both Jelfa and Adamed designate large amounts of funding for R&D projects. I believe that if a domestic enterprise acquires these shares, than this creates a huge opportunity for the domestic pharmaceuticals market," said Maciej Adamkiewicz, president of Adamed. Representatives stressed many times that they are mostly interested in a sector investor and currently the list of potential buyers consists of nine companies. "The more interested parties, the higher the quoted price for shares," said Arkadiusz Krężel, president of ARP. He went on to say that an investor will be chosen by the end of September. (Puls Biznesu, pp. 1, 9) M.M.